WO2022107673A1 - Beverage containing placenta and iron - Google Patents

Beverage containing placenta and iron Download PDF

Info

Publication number
WO2022107673A1
WO2022107673A1 PCT/JP2021/041452 JP2021041452W WO2022107673A1 WO 2022107673 A1 WO2022107673 A1 WO 2022107673A1 JP 2021041452 W JP2021041452 W JP 2021041452W WO 2022107673 A1 WO2022107673 A1 WO 2022107673A1
Authority
WO
WIPO (PCT)
Prior art keywords
iron
beverage
placenta extract
placenta
collagen peptide
Prior art date
Application number
PCT/JP2021/041452
Other languages
French (fr)
Japanese (ja)
Inventor
愛理 田中
美保 山下
麻里江 山地
Original Assignee
大正製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大正製薬株式会社 filed Critical 大正製薬株式会社
Priority to JP2021576325A priority Critical patent/JP7112040B1/en
Priority to JP2022008167A priority patent/JP2022081472A/en
Publication of WO2022107673A1 publication Critical patent/WO2022107673A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/66—Proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A23L33/165—Complexes or chelates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • the present invention can be used in the fields of pharmaceuticals, quasi-drugs, foods, etc. with respect to beverages containing animal placenta extract.
  • Animal placenta extract is an extract extracted from the placenta of mammals such as pigs, cows, horses, humans or sheep. Mammalian placenta tissue is rich in amino acids, active peptides, vitamins, minerals, sugars, enzymes, nucleic acids, etc., which are essential nutrients for fetal growth, and is an extract extracted from the mammalian placenta. Is called placenta extract (Patent Document 1). Since the animal placenta extract has a peculiar taste and odor, a masking technique when ingested as a beverage has been reported (Patent Document 2).
  • An object of the present invention is to provide a beverage having a low carbohydrate content, which suppresses the formation of precipitates derived from animal placenta extract.
  • the present inventors have unexpectedly found that the formation of a precipitate can be suppressed by blending an iron compound, and have completed the present invention. Further, they have found that the effect of suppressing precipitation formation is further enhanced by blending an iron compound and a collagen peptide, and have completed the present invention.
  • the aspects of the present invention obtained from such findings are as follows.
  • the iron compound is ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, sodium ferrous citrate, ferrous gluconate, iron lactate, ferrous pyrophosphate, pyrrolin.
  • the beverage according to (1) to (3) which is at least one selected from the group consisting of ferric acid acid, ferrous sulfate and iron hem.
  • the beverage according to (2) to (6), wherein the content of collagen peptide is 0.02 to 20 w / v%.
  • the beverage according to (1) to (7) which has a pH of 2.5 to 4.5.
  • a method for suppressing precipitation formation which comprises blending an iron compound in a beverage containing animal placenta extract.
  • a method for suppressing precipitation formation which comprises an iron compound and a collagen peptide in a beverage containing animal placenta extract. Is.
  • the animal placenta which is the raw material of the animal placenta extract used in the present invention, is not particularly limited, and is, for example, an edible placenta obtained as a postpartum at the time of full-term delivery of a healthy animal properly bred on a farm, such as the uterus. It is a marine placenta-like substance that does not contain external organs or is contained in the placenta of fish and the like.
  • the origin thereof is not particularly limited, and examples thereof include humans, cows, pigs, horses, sheep, and salmon, but pigs, horses, and salmon are preferable, and pigs are more preferable.
  • the form of the animal placenta extract is not particularly limited, and is, for example, a liquid or paste obtained through an extraction step after being decomposed by a method such as enzymatic decomposition or hydrochloric acid decomposition, and may be freeze-dried or spray-dried. , It may be in the form of a powder from which water has been removed.
  • animal placenta extract of the present invention a commercially available product may be used, for example, "Pig Placenta Extract AL-20” (manufactured by Sankyo Biochemicals Co., Ltd.) and "Horse Placenta Extract AL-20” (Sankyo Bio Co., Ltd.).
  • the content of the animal placenta extract of the present invention is preferably 0.001 to 4 w / v%, more preferably 0.01 to 2 w / v%, and further preferably 0.02 to 2 w / v% in the beverage of the present invention.
  • the placenta-equivalent amount is preferably 0.025 to 100 w / v%, more preferably 0.25 to 50 w / v%.
  • the "placenta-equivalent amount" is the amount of placenta required to obtain the placenta extract.
  • the content of the placenta extract is preferably 0.005 to 20000 parts by mass, more preferably 0.025 to 2000 parts by mass with respect to 1 part by mass of iron in terms of iron compound (iron equivalent) described later. It is preferable, 0.5 to 1000 parts by mass is more preferable, and 10 to 200 parts by mass is particularly preferable. In terms of placenta, 0.125 to 500,000 parts by mass is preferable, 0.625 to 50,000 parts by mass is more preferable, and 12.5 to 25,000 parts by mass is most preferable with respect to 1 part by mass of the iron compound (iron equivalent).
  • the "iron compound” may be either a divalent iron compound or a trivalent iron compound, for example, ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, or ferrous citrate.
  • a divalent iron compound for example, ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, or ferrous citrate.
  • examples thereof include sodium monoferric acid, ferrous gluconate, iron lactate, ferrous pyrophosphate, ferric pyrophosphate, ferrous sulfate and hem iron.
  • trivalent iron compounds such as ferric chloride, iron citrate, ammonium iron citrate and ferric pyrophosphate are preferable.
  • the content of the iron compound in the beverage of the present invention is preferably 0.0002 to 0.2 w / v%, more preferably 0.001 to 0.1 w / v%, and 0.002 to 0.04 w in terms of iron. / V% is more preferred.
  • the iron compound is preferably 0.001 to 2.0 w / v%, more preferably 0.005 to 1.2 w / v%, and even more preferably 0.01 to 0.5 w / v%.
  • the iron compound content in the beverage of the present invention preferably has an upper limit of 0.2 w / v%, more preferably 0.1 w / v%, and 0.04 w / v in terms of iron. v% is most preferable.
  • the content of the iron compound in the beverage of the present invention is preferably 1 mg to 20 mg in terms of iron per oral intake.
  • the single oral intake is the amount by which the beverage of the present invention is orally ingested at one time, for example, 30 to 200 ml, typically 30 ml, 50 ml, 100 ml, 150 ml, 200 ml.
  • the amount is, for example, 15 to 200 g, typically 15 g, 30 g, 50 g, 100 g, 150 g, 150 g, 200 g.
  • the form of the oral liquid container or the beverage container is not particularly limited.
  • the capacity of the container is not particularly limited, but can be, for example, 30 ml to 200 ml (typically 50 ml, 100 ml, 150 ml, or 200 ml).
  • the beverage of the present invention has a carbohydrate content of 0 to 40 w / v%, more preferably 0 to 20 w / v%, still more preferably 0 to 15% w / v%, and particularly preferably 0 to 0 to. It is 10 w / v%.
  • Carbohydrates include sugar, high fructose corn syrup, fructose, fructose-fructose syrup, fructose-fructose syrup, honey, starch syrup, powdered starch syrup, maltodextrin, sorbitol, martitol, reduced starch syrup, maltose, trehalose, brown sugar, etc. Examples thereof include organic acids such as citric acid and fructose.
  • the calorie of the beverage of the present invention is preferably 0 to 150 kcal / 100 ml, more preferably 0 to 100 kcal / 100 ml, and even more preferably 0 to 70 kcal / 100 ml.
  • the origin of the "collagen peptide” is not particularly limited and may be synthetic, and the skin, bone, ligament, tendon, and cartilage produced as a by-product when processing livestock such as cows and pigs and fish It may be a collagen peptide produced by extracting from the above, but a collagen peptide derived from pig and fish is preferable.
  • a collagen peptide obtained by decomposing collagen protein by enzyme, chemical treatment or the like is preferable.
  • the average molecular weight of the collagen peptide is not particularly limited, but is preferably 500 to 50,000, and more preferably 1,000 to 25,000.
  • collagen peptide of the present invention a commercially available product may be used, for example, "Nippi Peptide PS-1” (registered trademark, manufactured by Nippi Co., Ltd.), “Nippi Peptide PRA-P” (registered trademark, manufactured by Nippi Co., Ltd.).
  • the content of collagen peptide is preferably 0.02 to 20 w / v%, more preferably 0.1 to 15 w / v%, still more preferably 0.2 to 15 w / v% in the beverage of the present invention. ..
  • the content of collagen peptide is preferably 0.1 to 100,000 parts by mass, more preferably 0.5 to 10,000 parts by mass, based on 1 part by mass of iron in terms of iron compound (iron equivalent). It is more preferably 7500 parts by mass, and particularly preferably 20 to 7500 parts by mass. Further, 0.005 to 20000 parts by mass is preferable, 0.01 to 1000 parts by mass is more preferable, 0.1 to 750 parts by mass is further preferable, and 0.5 to 150 parts by mass is preferable with respect to 1 part by mass of placenta extract. Especially preferable.
  • placenta extract When the placenta extract is converted into a placenta, 0.0002 to 800 parts by mass is preferable, 0.002 to 40 parts by mass is more preferable, 0.004 to 30 parts by mass is more preferable, and 0 is 0 parts by mass of the placenta. .02 to 6 parts by mass is particularly preferable.
  • the present invention can suppress the formation of a precipitate derived from animal placenta extract by blending an iron compound. Further, when collagen peptide is further added, the effect of suppressing the formation of the precipitate derived from the animal placenta extract is enhanced.
  • the animal placenta is not particularly limited, but when the formation of the precipitate is suppressed only by the iron compound, the pig-derived animal placenta is particularly preferable.
  • the beverage in the present invention is not particularly limited as long as it is a liquid that can be orally ingested, and is a drug, a non-medicinal product, or a food (not only general foods, but also nutritionally functional foods, foods for specified health uses, and foods with functional claims). Also included).
  • Examples of pharmaceuticals and quasi-drugs include internal liquids and drinks. Examples of foods include soft drinks, carbonated drinks, sports / functional drinks, non-alcoholic drinks, dairy drinks, tea drinks, coffee drinks, fruit / vegetable drinks, jelly drinks and the like. More preferably, it is an internal liquid or drink for pharmaceuticals and quasi-drugs, and various beverages such as nutritional functional foods and foods for specified health use, carbonated beverages and jelly beverages for foods.
  • the pH of the beverage of the present invention is not particularly limited, but is preferably 2.5 to 4.5, more preferably 3.0 to 4.0, from the viewpoint of good mouthfeel.
  • a pH adjuster such as an organic acid can be added as needed.
  • the beverage of the present invention can be produced by a conventional method, and the method is not particularly limited. Usually, it is obtained by weighing each component, dissolving and stirring with an appropriate amount of purified water, adjusting the pH, further adding purified water to adjust the volume, and performing filtration and sterilization treatment as necessary.
  • the beverage of the present invention as other components, vitamins, minerals, amino acids and salts thereof, crude drugs, crude drug extracts, caffeine, royal jelly, dextrin and the like are appropriately added as long as the effects of the present invention are not impaired. Can be blended. Further, if necessary, additives such as antioxidants, colorants, flavors, flavoring agents, preservatives, sweeteners, and acidulants can be appropriately blended as long as the effects of the present invention are not impaired.
  • Beverages with the formulations listed in Table 1 below were prepared according to the following method. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted to 60 v / v% of the total amount to obtain an acidulant solution. Next, ammonium iron citrate was dissolved in purified water and the volume was adjusted so as to contain 0.2 to 0.4 w / v% as iron to obtain an iron solution. To the acidulant solution, add an iron solution or iron compound and pig-derived animal placenta extract (P-placenta extract manufactured by Nippon Ham Co., Ltd.) as necessary so that the formulation shown in the table is obtained, and the total amount is 90v /.
  • P-placenta extract manufactured by Nippon Ham Co., Ltd. pig-derived animal placenta extract manufactured by Nippon Ham Co., Ltd.
  • Examples 1-1 to 4-1 Purified water was added so as to be about v%, and the mixture was sufficiently stirred. After sufficient stirring, the pH was adjusted with hydrochloric acid or sodium hydroxide, and purified water was added to make the total amount to obtain a beverage (Examples 1-1 to 4-1). These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes. Beverages to which ammonium ferric citrate was not added (Comparative Examples 1 to 4) were used as controls. The beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
  • Example 1-1 for Comparative Example 1, Examples 2-1 to 2-3 for Comparative Example 2, and Examples 3-1 to 3-5 for Comparative Example 3-1.
  • Example 4-1 precipitation formation was suppressed by blending the iron compound.
  • the beverages of the formulations shown in Tables 3 and 4 below were prepared according to the following methods. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted to 60 v / v% of the total amount with purified water to obtain an acidulant solution. Next, ammonium iron citrate was dissolved in purified water, and the volume was adjusted so as to contain 0.2 to 0.4 w / v% as iron to obtain an iron solution. If necessary, add an iron solution or an iron compound to the acidulant solution so as to be as shown in the table, and add pig-derived animal placenta extract (P-placenta extract manufactured by Nippon Ham Co., Ltd.) and collagen peptide.
  • P-placenta extract manufactured by Nippon Ham Co., Ltd.
  • Example 42 Collagen peptide derived from pigs (molecular weight about 5000) is Korapep JB (registered trademark, manufactured by Nitta Gelatin Co., Ltd.), and collagen peptide derived from pigs (molecular weight about 4000-12000) is Nippi Peptide PRA-P (registered trademark, manufactured by Nitta Gelatin Co., Ltd.).
  • Nippi Peptide FCP-EX (registered trademark, manufactured by Nippi Co., Ltd.) was used as the collagen peptide derived from fish (manufactured by Nippi) and fish-derived collagen peptide (molecular weight of about 4000). These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes. Beverages to which ammonium iron citrate and collagen peptide were not added (Comparative Examples 1 to 4) were used as controls. The beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
  • Beverages with the formulations listed in Table 5 below were prepared according to the following method. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted with purified water having a total amount of about 60 v / v% to obtain an acidulant solution. Next, sodium ferrous citrate, pig-derived animal placenta extract (P-placenta extract manufactured by Nippon Ham Co., Ltd.) and collagen peptide are added in order, and purified water is added so that the total amount is about 90 v / v%. , Stirred well.
  • citric acid citric acid monohydrate
  • sodium benzoate sodium benzoate
  • Example 3-14 a beverage
  • These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes.
  • the beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
  • a beverage to which sodium ferrous citrate and collagen peptide were not added (Comparative Example 3-1) was used as a control.
  • Beverages with the formulations listed in Table 6 below were prepared according to the following method. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted to 60 v / v% of the total amount with purified water to obtain an acidulant solution. Next, ammonium iron citrate was dissolved in purified water, and the volume was adjusted so as to contain 0.4 w / v% as iron to obtain an iron solution. Add an iron solution to the acidulant solution according to the formulation shown in the table, and add salmon-derived placenta extract (Japan Barrier Free Marine Placenta (MP)) or horse-derived placenta extract (Dard Co., Ltd. horse).
  • MP Job Barrier Free Marine Placenta
  • the melon placenta-derived plant placenta extract was blended to obtain a beverage by the same method as the preparation in Table 1 or Table 3 (Comparative Examples 7-1 to 8-). 2).
  • These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes.
  • the beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2. Beverages to which ammonium iron citrate and collagen peptide were not added (Comparative Examples 7-1 and 8-1) were used as controls.

Abstract

The present invention addresses the problem of providing a beverage which is reduced in the production of precipitates derived from an animal placenta extract and has a reduced carbohydrate content. The beverage according to the present invention which solves the problem is characterized by comprising an animal placenta extract and an iron compound and having a carbohydrate content of 40 w/v% or less.

Description

プラセンタと鉄を含む飲料Beverage containing placenta and iron
　本発明は、動物プラセンタエキスを含有する飲料に関し、医薬品、医薬部外品及び食品等の分野において利用されうる。 The present invention can be used in the fields of pharmaceuticals, quasi-drugs, foods, etc. with respect to beverages containing animal placenta extract.
　近年、動物プラセンタエキスを配合した飲料やサプリメントの人気が高まっている。動物プラセンタエキスはブタ、ウシ、ウマ、ヒト又はヒツジなどの哺乳動物の胎盤から抽出されたエキスである。哺乳動物の胎盤組織には、胎児の成長に不可欠な栄養素であるアミノ酸、活性ペプチド、ビタミン、ミネラル、糖類、酵素、核酸などが豊富に蓄えられており、前記哺乳動物の胎盤から抽出されたエキスをプラセンタエキスという（特許文献１）。動物プラセンタエキスは特有の味やにおいを有しているため、飲料として摂取する際のマスキング技術が報告されている（特許文献２）。 In recent years, beverages and supplements containing animal placenta extract have become more popular. Animal placenta extract is an extract extracted from the placenta of mammals such as pigs, cows, horses, humans or sheep. Mammalian placenta tissue is rich in amino acids, active peptides, vitamins, minerals, sugars, enzymes, nucleic acids, etc., which are essential nutrients for fetal growth, and is an extract extracted from the mammalian placenta. Is called placenta extract (Patent Document 1). Since the animal placenta extract has a peculiar taste and odor, a masking technique when ingested as a beverage has been reported (Patent Document 2).
特開２０１１－１６０７４２号公報Japanese Unexamined Patent Publication No. 2011-160742 特開２０１８－１６６４４３号公報Japanese Unexamined Patent Publication No. 2018-166443
　健康意識の高い消費者にとって、砂糖や果糖ぶどう糖液糖のような炭水化物を多く含んだ製品は好ましくない。そこで本発明者らは、動物プラセンタエキスを配合し、かつ、炭水化物の含有量の少ない飲料を調製したところ、沈殿が生成することを発見した。外観や舌触りといった商品性の観点から、沈殿の生成は少しでも抑制されるべきであるが、今までに、動物プラセンタエキスを炭水化物の含有量の少ない飲料に配合した際の、動物プラセンタエキス由来の沈殿生成を抑制する方法については報告されていない。 For health-conscious consumers, products containing a large amount of carbohydrates such as sugar and high fructose corn syrup are not preferable. Therefore, the present inventors have found that when a beverage containing animal placenta extract and having a low carbohydrate content is prepared, a precipitate is formed. From the viewpoint of commerciality such as appearance and texture, the formation of precipitates should be suppressed as much as possible, but until now, the animal placenta extract has been derived from the animal placenta extract when it is blended into a beverage containing a low carbohydrate content. No method for suppressing precipitation formation has been reported.
　本発明の目的は、動物プラセンタエキス由来の沈殿生成を抑制した、炭水化物含有量の少ない飲料を提供することである。 An object of the present invention is to provide a beverage having a low carbohydrate content, which suppresses the formation of precipitates derived from animal placenta extract.
　本発明者らは、この問題を解決すべく鋭意検討を重ねた結果、意外にも、鉄化合物を配合すると沈殿生成を抑制できることを見出し、本発明を完成するに至った。また、鉄化合物とコラーゲンペプチドを配合すると、沈殿生成抑制効果が一層高まることを見出し、本発明を完成するに至った。 As a result of diligent studies to solve this problem, the present inventors have unexpectedly found that the formation of a precipitate can be suppressed by blending an iron compound, and have completed the present invention. Further, they have found that the effect of suppressing precipitation formation is further enhanced by blending an iron compound and a collagen peptide, and have completed the present invention.
　かかる知見により得られた本発明の態様は次のとおりである。
（１）動物プラセンタエキス、及び鉄化合物を含有し、炭水化物含有量が４０ｗ／ｖ％以下である飲料、
（２）さらにコラーゲンペプチドを含有する（１）に記載の飲料、
（３）鉄化合物の含有量が、鉄換算で０．０００２～０．２ｗ／ｖ％である（１）に記載の飲料、
（４）鉄化合物が、フマル酸第一鉄、塩化第二鉄、クエン酸鉄、クエン酸鉄アンモニウム、クエン酸第一鉄ナトリウム、グルコン酸第一鉄、乳酸鉄、ピロリン酸第一鉄、ピロリン酸第二鉄、硫酸第一鉄およびヘム鉄からなる群から選ばれる少なくとも１種である（１）～（３）に記載の飲料、
（５）動物プラセンタエキスの含有量が、０．００１～４ｗ／ｖ％である（１）～（４）に記載の飲料、
（６）動物プラセンタエキスの含有量が、胎盤換算で０．０２５～１００ｗ／ｖ％である（１）～（５）に記載の飲料、
（７）コラーゲンペプチドの含有量が、０．０２～２０ｗ／ｖ％である（２）～（６）に記載の飲料、
（８）ｐＨが２．５～４．５である（１）～（７）に記載の飲料、
（９）飲料が、液体飲料である（１）～（８）に記載の飲料、
（１０）動物プラセンタエキスを含有する飲料において、鉄化合物を配合することを特徴とする沈殿生成抑制方法、
（１１）動物プラセンタエキスを含有する飲料において、鉄化合物及びコラーゲンペプチドを特徴とする沈殿生成抑制方法、
である。 The aspects of the present invention obtained from such findings are as follows.
(1) Beverages containing animal placenta extract and iron compounds and having a carbohydrate content of 40 w / v% or less.
(2) The beverage according to (1), which further contains a collagen peptide.
(3) The beverage according to (1), wherein the content of the iron compound is 0.0002 to 0.2 w / v% in terms of iron.
(4) The iron compound is ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, sodium ferrous citrate, ferrous gluconate, iron lactate, ferrous pyrophosphate, pyrrolin. The beverage according to (1) to (3), which is at least one selected from the group consisting of ferric acid acid, ferrous sulfate and iron hem.
(5) The beverage according to (1) to (4), wherein the content of the animal placenta extract is 0.001 to 4 w / v%.
(6) The beverage according to (1) to (5), wherein the content of the animal placenta extract is 0.025 to 100 w / v% in terms of placenta.
(7) The beverage according to (2) to (6), wherein the content of collagen peptide is 0.02 to 20 w / v%.
(8) The beverage according to (1) to (7), which has a pH of 2.5 to 4.5.
(9) The beverage according to (1) to (8), wherein the beverage is a liquid beverage.
(10) A method for suppressing precipitation formation, which comprises blending an iron compound in a beverage containing animal placenta extract.
(11) A method for suppressing precipitation formation, which comprises an iron compound and a collagen peptide in a beverage containing animal placenta extract.
Is.
　本発明により、動物プラセンタエキスを配合し、沈殿生成が抑制された炭水化物含有量の少ない飲料を提供することが可能となった。 According to the present invention, it has become possible to provide a beverage containing an animal placenta extract and having a low carbohydrate content in which precipitation is suppressed.
　本発明に用いる動物プラセンタエキスの原料である動物プラセンタは、特に限定されないが、例えば、適正に農場にて飼育された健康な動物の満期出産時に後産として得られる食用の胎盤で、子宮などの外的器官を含んでいないものや、魚などの卵巣膜に含まれる海洋性のプラセンタ様物質のことである。また、その起源についても特に限定されず、例えばヒト、牛、豚、馬、羊、鮭などが挙げられるが、好ましくは豚、馬、鮭であり、より好ましくは豚である。
　動物プラセンタエキスの形態は特に制限されるものではなく、例えば、酵素分解、塩酸分解などの方法により分解後、抽出工程を経て得られた液体やペーストであり、凍結乾燥、噴霧乾燥などの方法により、水分を除去した粉末状のものであってもよい。 The animal placenta, which is the raw material of the animal placenta extract used in the present invention, is not particularly limited, and is, for example, an edible placenta obtained as a postpartum at the time of full-term delivery of a healthy animal properly bred on a farm, such as the uterus. It is a marine placenta-like substance that does not contain external organs or is contained in the placenta of fish and the like. The origin thereof is not particularly limited, and examples thereof include humans, cows, pigs, horses, sheep, and salmon, but pigs, horses, and salmon are preferable, and pigs are more preferable.
The form of the animal placenta extract is not particularly limited, and is, for example, a liquid or paste obtained through an extraction step after being decomposed by a method such as enzymatic decomposition or hydrochloric acid decomposition, and may be freeze-dried or spray-dried. , It may be in the form of a powder from which water has been removed.
　本発明の動物プラセンタエキスは、市販品を用いてもよく、例えば、「豚プラセンタエキスＡＬ－２０」（（株）三共バイオケミカルズ製）、「馬プラセンタエキスＡＬ－２０」（（株）三共バイオケミカルズ製）、「食品用馬プラセンタエキス末（HPA）（（株）ダード製）」「プラセンタエキスＰ-Ｆ」（一丸ファルコス（株）製）、「プラセンタパウダーＴ－１００」（一丸ファルコス（株）製）、「Ｐ－プラセンタエキスＧ」（日本ハム（株）製）、「Ｐ－プラセンタリキッド」（日本ハム（株）製）、「Ｐ－プラセンタエキス」（日本ハム（株）製）、「ＳＰＦプラセンタＴ－ＡＳ」（東洋酵素化学（株）製）、「ＳＰＦプラセンタＴ－１００Ｓ」（東洋酵素化学（株）製）「マリンプラセンタ（ＭＰ）（登録商標、（株）日本バリアフリー製）」等が挙げられる。 As the animal placenta extract of the present invention, a commercially available product may be used, for example, "Pig Placenta Extract AL-20" (manufactured by Sankyo Biochemicals Co., Ltd.) and "Horse Placenta Extract AL-20" (Sankyo Bio Co., Ltd.). Chemicals), "Food Horse Placenta Extract Powder (HPA) (Dard Co., Ltd.)" "Placenta Extract PF" (Ichimaru Falcos Co., Ltd.), "Placenta Powder T-100" (Ichimaru Falcos Co., Ltd.) ), "P-Placenta Extract G" (manufactured by Nippon Ham Co., Ltd.), "P-Placenta Liquid" (manufactured by Nippon Ham Co., Ltd.), "P-Placenta Extract" (manufactured by Nippon Ham Co., Ltd.), "SPF Placenta T-AS" (manufactured by Toyo Enzyme Chemical Co., Ltd.), "SPF Placenta T-100S" (manufactured by Toyo Enzyme Chemical Co., Ltd.) "Marine Placenta (MP) (registered trademark, manufactured by Japan Barrier Free Co., Ltd.)" ) ”And so on.
　本発明の動物プラセンタエキスの含有量は、本発明の飲料中、０．００１～４ｗ／ｖ％が好ましく、０．０１～２ｗ／ｖ％がより好ましく、０．０２～２ｗ／ｖ％がさらに好ましい。また、胎盤換算量で０．０２５～１００ｗ／ｖ％が好ましく、０．２５～５０ｗ／ｖ％がより好ましい。ここで「胎盤換算量」とは、プラセンタエキスを得るために必要な胎盤量である。
　プラセンタエキスの含有量は、本発明の効果の点から、後述する鉄化合物（鉄換算）で鉄１質量部に対して０．００５～２００００質量部が好ましく、０．０２５～２０００質量部がより好ましく、０．５～１０００質量部がさらに好ましく、１０～２００質量部が特に好ましい。また、胎盤換算では、鉄化合物（鉄換算）１質量部に対して０．１２５～５０００００質量部が好ましく、０．６２５～５００００質量部がより好ましく、１２．５～２５０００質量部が最も好ましい。 The content of the animal placenta extract of the present invention is preferably 0.001 to 4 w / v%, more preferably 0.01 to 2 w / v%, and further preferably 0.02 to 2 w / v% in the beverage of the present invention. preferable. The placenta-equivalent amount is preferably 0.025 to 100 w / v%, more preferably 0.25 to 50 w / v%. Here, the "placenta-equivalent amount" is the amount of placenta required to obtain the placenta extract.
From the viewpoint of the effect of the present invention, the content of the placenta extract is preferably 0.005 to 20000 parts by mass, more preferably 0.025 to 2000 parts by mass with respect to 1 part by mass of iron in terms of iron compound (iron equivalent) described later. It is preferable, 0.5 to 1000 parts by mass is more preferable, and 10 to 200 parts by mass is particularly preferable. In terms of placenta, 0.125 to 500,000 parts by mass is preferable, 0.625 to 50,000 parts by mass is more preferable, and 12.5 to 25,000 parts by mass is most preferable with respect to 1 part by mass of the iron compound (iron equivalent).
　本発明において「鉄化合物」としては、二価の鉄化合物及び三価の鉄化合物のいずれでもよく、例えばフマル酸第一鉄、塩化第二鉄、クエン酸鉄、クエン酸鉄アンモニウム、クエン酸第一鉄ナトリウム、グルコン酸第一鉄、乳酸鉄、ピロリン酸第一鉄、ピロリン酸第二鉄、硫酸第一鉄およびヘム鉄を挙げることができる。鉄化合物のみで沈殿生成を抑制する場合は、塩化第二鉄、クエン酸鉄、クエン酸鉄アンモニウム及びピロリン酸第二鉄等の三価の鉄化合物が好ましい。 In the present invention, the "iron compound" may be either a divalent iron compound or a trivalent iron compound, for example, ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, or ferrous citrate. Examples thereof include sodium monoferric acid, ferrous gluconate, iron lactate, ferrous pyrophosphate, ferric pyrophosphate, ferrous sulfate and hem iron. When the precipitation formation is suppressed only by the iron compound, trivalent iron compounds such as ferric chloride, iron citrate, ammonium iron citrate and ferric pyrophosphate are preferable.
　鉄化合物の含有量は、本発明の飲料中、鉄換算で０．０００２～０．２ｗ／ｖ％が好ましく、０．００１～０．１ｗ／ｖ％がより好ましく、０．００２～０．０４ｗ／ｖ％がさらに好ましい。また、鉄化合物としては、０．００１～２．０ｗ／ｖ％が好ましく、０．００５～１．２ｗ／ｖ％がより好ましく、０．０１～０．５ｗ／ｖ％がさらに好ましい。また、風味の点から、鉄化合物の含有量は、本発明の飲料中、鉄換算としては上限値は０．２ｗ／ｖ％が好ましく、０．１ｗ／ｖ％がより好ましく、０．０４ｗ／ｖ％が最も好ましい。 The content of the iron compound in the beverage of the present invention is preferably 0.0002 to 0.2 w / v%, more preferably 0.001 to 0.1 w / v%, and 0.002 to 0.04 w in terms of iron. / V% is more preferred. The iron compound is preferably 0.001 to 2.0 w / v%, more preferably 0.005 to 1.2 w / v%, and even more preferably 0.01 to 0.5 w / v%. Further, from the viewpoint of flavor, the iron compound content in the beverage of the present invention preferably has an upper limit of 0.2 w / v%, more preferably 0.1 w / v%, and 0.04 w / v in terms of iron. v% is most preferable.
　また、本発明の飲料における鉄化合物の含有量は、好ましくは一回の経口摂取量当たり、鉄換算で、１ｍｇ～２０ｍｇがより好ましい。また、一回の経口摂取量とは、本発明の飲料が一度に経口摂取される量であり、例えば、３０～２００ｍｌ、典型的には３０ｍｌ、５０ｍｌ、１００ｍｌ、１５０ｍｌ、２００ｍｌがその量であり、ゼリー状の形態である場合には、例えば１５～２００ｇ、典型的には１５ｇ、３０ｇ、５０ｇ、１００ｇ、１５０ｇ、１５０ｇ、２００ｇがその量である。また、経口液体用容器又は飲料用容器の形態は特に限定されない。容器の容量は特に限定されないが、例えば３０ｍｌ～２００ｍｌ（典型的には５０ｍｌ、１００ｍｌ、１５０ｍｌ、又は２００ｍｌ）とすることができる。 Further, the content of the iron compound in the beverage of the present invention is preferably 1 mg to 20 mg in terms of iron per oral intake. The single oral intake is the amount by which the beverage of the present invention is orally ingested at one time, for example, 30 to 200 ml, typically 30 ml, 50 ml, 100 ml, 150 ml, 200 ml. In the case of a jelly-like form, the amount is, for example, 15 to 200 g, typically 15 g, 30 g, 50 g, 100 g, 150 g, 150 g, 200 g. Further, the form of the oral liquid container or the beverage container is not particularly limited. The capacity of the container is not particularly limited, but can be, for example, 30 ml to 200 ml (typically 50 ml, 100 ml, 150 ml, or 200 ml).
　本発明の飲料は、炭水化物の含有量０～４０ｗ／ｖ％であり、より好ましくは０～２０ｗ／ｖ％であり、さらに好ましくは０～１５％ｗ／ｖ％であり、特に好ましくは０～１０ｗ／ｖ％である。「炭水化物」としては、砂糖、異性化糖、果糖、果糖ぶどう糖液糖、ぶどう糖果糖液糖、はちみつ、水飴、粉飴、マルトデキストリン、ソルビトール、マルチトール、還元水飴、マルトース、トレハロース、黒糖等や、クエン酸やリンゴ酸等の有機酸が挙げられる。 The beverage of the present invention has a carbohydrate content of 0 to 40 w / v%, more preferably 0 to 20 w / v%, still more preferably 0 to 15% w / v%, and particularly preferably 0 to 0 to. It is 10 w / v%. "Carbohydrates" include sugar, high fructose corn syrup, fructose, fructose-fructose syrup, fructose-fructose syrup, honey, starch syrup, powdered starch syrup, maltodextrin, sorbitol, martitol, reduced starch syrup, maltose, trehalose, brown sugar, etc. Examples thereof include organic acids such as citric acid and fructose.
　また、本発明の飲料のカロリーは、０～１５０ｋｃａｌ／１００ｍｌが好ましく、より好ましくは０～１００ｋｃａｌ／１００ｍｌ、さらにより好ましくは０～７０ｋｃａｌ／１００ｍｌである。 The calorie of the beverage of the present invention is preferably 0 to 150 kcal / 100 ml, more preferably 0 to 100 kcal / 100 ml, and even more preferably 0 to 70 kcal / 100 ml.
　本発明において「コラーゲンペプチド」とは、その起源は特に限定されず、合成であってもよく、牛や豚等の家畜や魚を加工する際に副生する皮、骨、靭帯、腱、軟骨等から抽出して製造されるコラーゲンペプチドであってもよいが、豚および魚由来のコラーゲンペプチドが好ましい。コラーゲンタンパク質を酵素や化学的処理等により分解して得られるコラーゲンペプチドが好ましい。
　コラーゲンペプチドの平均分子量としては、特に限定されないが、５００～５００００であることが好ましく、１０００～２５０００であることがより好ましい。本発明のコラーゲンペプチドは、市販品を用いてもよく、例えば「ニッピペプタイドＰＳ－１」（登録商標、（株）ニッピ製）、「ニッピペプタイドＰＲＡ－Ｐ」（登録商標、（株）ニッピ製）、「ニッピペプタイドＦＣＰ－ＥＸ」（登録商標、（株）ニッピ製）、「ＨＡＣＰ－ＣＦ」（ゼライス（株）製）、「ＨＡＣＰ－ＴＦ」（ゼライス（株）製）、「コラペプＰＵ」（登録商標、新田ゼラチン（株）製）、「コラペプＪＢ」（登録商標、新田ゼラチン（株）製）、「ＨＤＬ－５０ＳＰ」（新田ゼラチン（株）製）、「ＳＣＰ－３１００」（新田ゼラチン（株）製）、「ｐｅｐｔａｎ　Ｐ２０００ＨＤ」（ルスロ（株）製）等が挙げられる。 In the present invention, the origin of the "collagen peptide" is not particularly limited and may be synthetic, and the skin, bone, ligament, tendon, and cartilage produced as a by-product when processing livestock such as cows and pigs and fish It may be a collagen peptide produced by extracting from the above, but a collagen peptide derived from pig and fish is preferable. A collagen peptide obtained by decomposing collagen protein by enzyme, chemical treatment or the like is preferable.
The average molecular weight of the collagen peptide is not particularly limited, but is preferably 500 to 50,000, and more preferably 1,000 to 25,000. As the collagen peptide of the present invention, a commercially available product may be used, for example, "Nippi Peptide PS-1" (registered trademark, manufactured by Nippi Co., Ltd.), "Nippi Peptide PRA-P" (registered trademark, manufactured by Nippi Co., Ltd.). ), "Nippi Peptide FCP-EX" (registered trademark, manufactured by Nippi Co., Ltd.), "HACP-CF" (manufactured by Zerice Co., Ltd.), "HACP-TF" (manufactured by Zerice Co., Ltd.), "Collapep PU" (Registered trademark, manufactured by Nippi Gelatin Co., Ltd.), "Collapept JB" (Registered trademark, manufactured by Nitta Gelatin Co., Ltd.), "HDL-50SP" (manufactured by Nitta Gelatin Co., Ltd.), "SCP-3100" (Manufactured by Nitta Gelatin Co., Ltd.), "peptan P2000HD" (manufactured by Rusuro Co., Ltd.) and the like can be mentioned.
　コラーゲンペプチドの含有量は、本発明の飲料中、０．０２～２０ｗ／ｖ％であることが好ましく、０．１～１５ｗ／ｖ％がより好ましく、０．２～１５ｗ／ｖ％がさらに好ましい。 The content of collagen peptide is preferably 0.02 to 20 w / v%, more preferably 0.1 to 15 w / v%, still more preferably 0.2 to 15 w / v% in the beverage of the present invention. ..
　コラーゲンペプチドの含有量は、本発明の効果の点から、鉄化合物（鉄換算）で鉄１質量部に対し０．１～１０００００質量部が好ましく、０．５～１００００質量部がより好ましく、５～７５００質量部がさらに好ましく、２０～７５００質量部が特に好ましい。また、プラセンタエキス１質量部に対して０．００５～２００００質量部が好ましく、０．０１～１０００質量部がより好ましく、０．１～７５０質量部がさらに好ましく、０．５～１５０質量部が特に好ましい。なお、プラセンタエキスを胎盤に換算すると、胎盤として１質量部に対し０．０００２～８００質量部が好ましく、０．００２～４０質量部がより好ましく、０．００４～３０質量部がさらに好ましく、０．０２～６質量部が特に好ましい。 From the viewpoint of the effect of the present invention, the content of collagen peptide is preferably 0.1 to 100,000 parts by mass, more preferably 0.5 to 10,000 parts by mass, based on 1 part by mass of iron in terms of iron compound (iron equivalent). It is more preferably 7500 parts by mass, and particularly preferably 20 to 7500 parts by mass. Further, 0.005 to 20000 parts by mass is preferable, 0.01 to 1000 parts by mass is more preferable, 0.1 to 750 parts by mass is further preferable, and 0.5 to 150 parts by mass is preferable with respect to 1 part by mass of placenta extract. Especially preferable. When the placenta extract is converted into a placenta, 0.0002 to 800 parts by mass is preferable, 0.002 to 40 parts by mass is more preferable, 0.004 to 30 parts by mass is more preferable, and 0 is 0 parts by mass of the placenta. .02 to 6 parts by mass is particularly preferable.
　本発明は、動物プラセンタエキス由来の沈殿物の生成を、鉄化合物を配合することで抑制できる。また、さらにコラーゲンペプチドを配合すると、動物プラセンタエキス由来の沈殿物の生成抑制効果は大きくなる。動物プラセンタとしては特に限定されないが、鉄化合物のみで沈殿の生成を抑制する場合、豚由来動物プラセンタが特に好ましい。 The present invention can suppress the formation of a precipitate derived from animal placenta extract by blending an iron compound. Further, when collagen peptide is further added, the effect of suppressing the formation of the precipitate derived from the animal placenta extract is enhanced. The animal placenta is not particularly limited, but when the formation of the precipitate is suppressed only by the iron compound, the pig-derived animal placenta is particularly preferable.
　本発明における飲料とは、経口摂取できる液体であれば特に制限はなく、医薬品、医薬部外品、又は食品（一般の食品だけでなく、栄養機能性食品や特定保健用食品、機能性表示食品も含む）を挙げることができる。医薬品及び医薬部外品としては、例えば内服液剤、ドリンク剤等を挙げることができる。食品としては、清涼飲料水、炭酸飲料、スポーツ・機能性飲料、ノンアルコール飲料、乳飲料、茶飲料、コーヒー飲料、果実・野菜系飲料、ゼリー飲料等が挙げられる。より好ましくは、医薬品及び医薬部外品であれば内服液剤、ドリンク剤、食品であれば、栄養機能性食品、特定保健用食品等の各種飲料、炭酸飲料、ゼリー飲料である。 The beverage in the present invention is not particularly limited as long as it is a liquid that can be orally ingested, and is a drug, a non-medicinal product, or a food (not only general foods, but also nutritionally functional foods, foods for specified health uses, and foods with functional claims). Also included). Examples of pharmaceuticals and quasi-drugs include internal liquids and drinks. Examples of foods include soft drinks, carbonated drinks, sports / functional drinks, non-alcoholic drinks, dairy drinks, tea drinks, coffee drinks, fruit / vegetable drinks, jelly drinks and the like. More preferably, it is an internal liquid or drink for pharmaceuticals and quasi-drugs, and various beverages such as nutritional functional foods and foods for specified health use, carbonated beverages and jelly beverages for foods.
　本発明の飲料のｐＨは、特に限定されないが、口当たりの良さという点から２．５～４．５が好ましく、３．０～４．０がより好ましい。ｐＨを上記範囲に保つために、必要に応じて有機酸等のｐＨ調整剤を配合することができる。 The pH of the beverage of the present invention is not particularly limited, but is preferably 2.5 to 4.5, more preferably 3.0 to 4.0, from the viewpoint of good mouthfeel. In order to keep the pH in the above range, a pH adjuster such as an organic acid can be added as needed.
　本発明の飲料は、常法により製造することができ、その方法は特に限定されるものではない。通常、各成分を量りとり、適量の精製水で溶解、撹拌した後、ｐＨを調整し、さらに精製水を加えて容量調整し、必要に応じてろ過、殺菌処理を施すことにより得られる。 The beverage of the present invention can be produced by a conventional method, and the method is not particularly limited. Usually, it is obtained by weighing each component, dissolving and stirring with an appropriate amount of purified water, adjusting the pH, further adding purified water to adjust the volume, and performing filtration and sterilization treatment as necessary.
　また、本発明の飲料には、その他の成分として、ビタミン類、ミネラル類、アミノ酸及びその塩類、生薬、生薬抽出物、カフェイン、ローヤルゼリー、デキストリン等を本発明の効果を損なわない範囲で適宜に配合することができる。さらに必要に応じて、抗酸化剤、着色剤、香料、矯味剤、保存剤、甘味料、酸味剤等の添加物を本発明の効果を損なわない範囲で適宜に配合することができる。 Further, in the beverage of the present invention, as other components, vitamins, minerals, amino acids and salts thereof, crude drugs, crude drug extracts, caffeine, royal jelly, dextrin and the like are appropriately added as long as the effects of the present invention are not impaired. Can be blended. Further, if necessary, additives such as antioxidants, colorants, flavors, flavoring agents, preservatives, sweeteners, and acidulants can be appropriately blended as long as the effects of the present invention are not impaired.
　以下に、実施例、比較例を挙げ、本発明を更に詳細に説明する。 Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples.
　下記表１に記載の処方の飲料を次の方法に従い調製した。まず、クエン酸（クエン酸一水和物）と安息香酸ナトリウムを精製水で溶解し、全量の６０ｖ／ｖ％に容量調整し酸味剤液を得た。次に、クエン酸鉄アンモニウムを精製水で溶解し、鉄として０．２～０．４ｗ／ｖ％含むように容量調整し、鉄溶液を得た。酸味剤液に、表に示した処方となるように必要に応じて、鉄溶液または鉄化合物、豚由来動物プラセンタエキス（日本ハム（株）製　Ｐ－プラセンタエキス）を添加し、全量の９０ｖ／ｖ％程度となるように精製水を加え、十分に撹拌した。十分に撹拌後、塩酸または水酸化ナトリウムを用いてｐＨを調整し、精製水を加えて全量とし、飲料を得た（実施例１－１～４－１）。
　これらの飲料をスクリュー管Ｎｏ．７（（株）マルエム製）に５０ｍｌ充填し、８０℃２５分の殺菌を行った。クエン酸鉄アンモニウムを添加しない飲料（比較例１～４）を対照とした。
　上記の通り調製した飲料を６５℃で７日間保存し、沈殿を目視により観察した。表２の基準で沈殿生成度合いを評価した。 Beverages with the formulations listed in Table 1 below were prepared according to the following method. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted to 60 v / v% of the total amount to obtain an acidulant solution. Next, ammonium iron citrate was dissolved in purified water and the volume was adjusted so as to contain 0.2 to 0.4 w / v% as iron to obtain an iron solution. To the acidulant solution, add an iron solution or iron compound and pig-derived animal placenta extract (P-placenta extract manufactured by Nippon Ham Co., Ltd.) as necessary so that the formulation shown in the table is obtained, and the total amount is 90v /. Purified water was added so as to be about v%, and the mixture was sufficiently stirred. After sufficient stirring, the pH was adjusted with hydrochloric acid or sodium hydroxide, and purified water was added to make the total amount to obtain a beverage (Examples 1-1 to 4-1).
These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes. Beverages to which ammonium ferric citrate was not added (Comparative Examples 1 to 4) were used as controls.
The beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000002
　表１に示した通り、動物プラセンタエキスの配合により沈殿が生じ（比較例１、２、３－１、４）、動物プラセンタエキスの濃度が高まると沈殿生成の割合も増加した（比較例１～３－１）。一方、比較例１に対して実施例１－１、比較例２に対して実施例２－１～実施例２－３、比較例３－１に対して実施例３－１～３－５、比較例４に対して実施例４－１を比較して明白なように、鉄化合物を配合することにより沈殿生成が抑制された。 As shown in Table 1, precipitation occurred due to the formulation of the animal placenta extract (Comparative Examples 1, 2, 3-1 and 4), and the rate of precipitation formation increased as the concentration of the animal placenta extract increased (Comparative Examples 1 to 1 to 4). 3-1). On the other hand, Example 1-1 for Comparative Example 1, Examples 2-1 to 2-3 for Comparative Example 2, and Examples 3-1 to 3-5 for Comparative Example 3-1. As is clear from the comparison of Example 4-1 with Comparative Example 4, precipitation formation was suppressed by blending the iron compound.
　下記表３、表４に記載の処方の飲料を次の方法に従い調製した。まず、クエン酸（クエン酸一水和物）と安息香酸ナトリウムを精製水で溶解し、精製水で全量の６０ｖ／ｖ％に容量調整し、酸味剤液を得た。次に、クエン酸鉄アンモニウムを精製水で溶解し、鉄として０．２～０．４ｗ／ｖ％含むように容量調整し、鉄溶液を得た。酸味剤液に、表に示した処方となるように、必要に応じて鉄溶液または鉄化合物を添加し、豚由来動物プラセンタエキス（日本ハム（株）製　Ｐ－プラセンタエキス）及びコラーゲンペプチドを添加し、全量の９０ｖ／ｖ％程度となるように精製水を加え、十分に撹拌した。十分に撹拌後、塩酸または水酸化ナトリウムを用いてｐＨを調整し、精製水を加えて全量とし、飲料を得た（実施例１-２、実施例２－４、実施例３－６～３－１３、実施例４－２）。豚由来コラーゲンペプチド（分子量約５０００）はコラぺプＪＢ（登録商標、新田ゼラチン（株）製）、豚由来コラーゲンペプチド（分子量約４０００―１２０００）はニッピペプタイドPRA-P（登録商標、株式会社ニッピ製）、魚由来コラーゲンペプチド（分子量約４０００）はニッピペプタイドFCP-EX（登録商標、株式会社ニッピ製）を使用した。
　これらの飲料をスクリュー管Ｎｏ．７（（株）マルエム製）に５０ｍｌ充填し、８０℃２５分の殺菌を行った。クエン酸鉄アンモニウム及びコラーゲンペプチドを添加しない飲料（比較例１～４）を対照とした。
　上記の通り調製した飲料を６５℃で７日間保存し、沈殿を目視により観察した。表２の基準で沈殿生成度合いを評価した。 The beverages of the formulations shown in Tables 3 and 4 below were prepared according to the following methods. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted to 60 v / v% of the total amount with purified water to obtain an acidulant solution. Next, ammonium iron citrate was dissolved in purified water, and the volume was adjusted so as to contain 0.2 to 0.4 w / v% as iron to obtain an iron solution. If necessary, add an iron solution or an iron compound to the acidulant solution so as to be as shown in the table, and add pig-derived animal placenta extract (P-placenta extract manufactured by Nippon Ham Co., Ltd.) and collagen peptide. Then, purified water was added so that the total amount was about 90 v / v%, and the mixture was sufficiently stirred. After sufficient stirring, the pH was adjusted with hydrochloric acid or sodium hydroxide, and purified water was added to make the total amount to obtain a beverage (Examples 1-2, 2-4, 3-6 to 3). -13, Example 4-2). Collagen peptide derived from pigs (molecular weight about 5000) is Korapep JB (registered trademark, manufactured by Nitta Gelatin Co., Ltd.), and collagen peptide derived from pigs (molecular weight about 4000-12000) is Nippi Peptide PRA-P (registered trademark, manufactured by Nitta Gelatin Co., Ltd.). Nippi Peptide FCP-EX (registered trademark, manufactured by Nippi Co., Ltd.) was used as the collagen peptide derived from fish (manufactured by Nippi) and fish-derived collagen peptide (molecular weight of about 4000).
These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes. Beverages to which ammonium iron citrate and collagen peptide were not added (Comparative Examples 1 to 4) were used as controls.
The beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000004
Figure JPOXMLDOC01-appb-T000004
　表３、４に示した通り、動物プラセンタエキスの配合により沈殿が生じた（比較例１、２、３－１、４）。比較例１と実施例１－２、比較例２と実施例２－４、比較例３－１と実施例３－６～３－１１、比較例４と実施例４－２を比較して明白なように、鉄化合物およびコラーゲンペプチドを配合することにより沈殿生成が抑制された。
　また、表１の実施例３－２と比較して実施例３－７、実施例３－３と比較して実施例３－８、実施例３－４と比較して実施例３－９、実施例３－５と比較して実施例３－１１で沈殿生成が抑制されており、鉄化合物とコラーゲンペプチドを組み合わせることで沈殿生成抑制効果が向上した。 As shown in Tables 3 and 4, precipitation occurred by blending the animal placenta extract (Comparative Examples 1, 2, 3-1 and 4). It is clear by comparing Comparative Example 1 and Example 1-2, Comparative Example 2 and Example 2-4, Comparative Example 3-1 and Examples 3-6 to 3-11, and Comparative Example 4 and Example 4-2. As described above, the precipitation formation was suppressed by blending the iron compound and the collagen peptide.
In addition, Example 3-7 compared with Example 3-2 in Table 1, Example 3-8 compared with Example 3-3, and Example 3-9 compared with Example 3-4. Precipitation formation was suppressed in Example 3-11 as compared with Example 3-5, and the effect of suppressing precipitation formation was improved by combining the iron compound and the collagen peptide.
　下記表５に記載の処方の飲料を次の方法に従い調製した。まず、クエン酸（クエン酸一水和物）と安息香酸ナトリウムを精製水で溶解し、全量の６０ｖ／ｖ％程度の精製水で容量調整し、酸味剤液を得た。次に、クエン酸第一鉄ナトリウム、豚由来動物プラセンタエキス（日本ハム（株）製　Ｐ－プラセンタエキス）及びコラーゲンペプチドを順に添加し、全量の９０ｖ／ｖ％程度となるように精製水を加え、十分に撹拌した。十分に撹拌後、塩酸または水酸化ナトリウムを用いてｐＨを調整し、精製水を加えて全量とし、飲料を得た（実施例３－１４）。
　これらの飲料をスクリュー管Ｎｏ．７（（株）マルエム製）に５０ｍｌ充填し、８０℃２５分の殺菌を行った。上記の通り調製した飲料を６５℃で７日間保存し、沈殿を目視により観察した。表２の基準で沈殿生成度合いを評価した。
　クエン酸第一鉄ナトリウム及びコラーゲンペプチドを添加しない飲料（比較例３－１）を対照とした。 Beverages with the formulations listed in Table 5 below were prepared according to the following method. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted with purified water having a total amount of about 60 v / v% to obtain an acidulant solution. Next, sodium ferrous citrate, pig-derived animal placenta extract (P-placenta extract manufactured by Nippon Ham Co., Ltd.) and collagen peptide are added in order, and purified water is added so that the total amount is about 90 v / v%. , Stirred well. After sufficient stirring, the pH was adjusted with hydrochloric acid or sodium hydroxide, and purified water was added to make the total amount to obtain a beverage (Example 3-14).
These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes. The beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
A beverage to which sodium ferrous citrate and collagen peptide were not added (Comparative Example 3-1) was used as a control.
Figure JPOXMLDOC01-appb-T000005
Figure JPOXMLDOC01-appb-T000005
　表５に示す通り、クエン酸鉄アンモニウムの代わりにクエン酸第一鉄ナトリウムを配合した場合、鉄化合物の配合だけでは沈殿生成抑制効果は見られなかったが（比較例３－２）、比較例３－１と実施例３－１４に示した通り、コラーゲンペプチドを配合することで、クエン酸第一鉄ナトリウム及びコラーゲンを配合しない処方（比較例３－１）と比較して沈殿生成が抑制された（実施例３－１４）。 As shown in Table 5, when sodium ferrous citrate was blended instead of ammonium iron citrate, the effect of suppressing precipitation formation was not observed only by blending the iron compound (Comparative Example 3-2), but Comparative Example. As shown in 3-1 and Example 3-14, by blending the collagen peptide, precipitation formation is suppressed as compared with the formulation not blending sodium ferrous citrate and collagen (Comparative Example 3-1). (Example 3-14).
　下記表６に記載の処方の飲料を次の方法に従い調製した。まず、クエン酸（クエン酸一水和物）と安息香酸ナトリウムを精製水で溶解し、精製水で全量の６０ｖ／ｖ％に容量調整し、酸味剤液を得た。次に、クエン酸鉄アンモニウムを精製水で溶解し、鉄として０．４ｗ／ｖ％含むように容量調整し、鉄溶液を得た。酸味剤液に、表に示した処方となるように鉄溶液を添加し、鮭由来プラセンタエキス（（株）日本バリアフリー製　マリンプラセンタ（ＭＰ））または馬由来プラセンタエキス（（株）ダード製　馬由来プラセンタエキス末）及び必要に応じてコラーゲンペプチドを添加し、全量の９０ｖ／ｖ％程度となるように精製水を加え、十分に撹拌した。十分に撹拌後、塩酸または水酸化ナトリウムを用いてｐＨを調整し、精製水を加えて全量とし、飲料を得た（比較例５－２、６－２、実施例５、６）。
　これらの飲料をスクリュー管Ｎｏ．７（（株）マルエム製）に５０ｍｌ充填し、８０℃２５分の殺菌を行った。クエン酸鉄アンモニウム及びコラーゲンペプチドを添加しない飲料（比較例５－１、６－１）を対照とした。
　上記の通り調製した飲料を６５℃で７日間保存し、沈殿を目視により観察した。表２の基準で沈殿生成度合いを評価した。 Beverages with the formulations listed in Table 6 below were prepared according to the following method. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted to 60 v / v% of the total amount with purified water to obtain an acidulant solution. Next, ammonium iron citrate was dissolved in purified water, and the volume was adjusted so as to contain 0.4 w / v% as iron to obtain an iron solution. Add an iron solution to the acidulant solution according to the formulation shown in the table, and add salmon-derived placenta extract (Japan Barrier Free Marine Placenta (MP)) or horse-derived placenta extract (Dard Co., Ltd. horse). (Derived placenta extract powder) and collagen peptide as needed were added, purified water was added so that the total amount was about 90 v / v%, and the mixture was sufficiently stirred. After sufficient stirring, the pH was adjusted with hydrochloric acid or sodium hydroxide, and purified water was added to make the total amount to obtain a beverage (Comparative Examples 5-2, 6-2, Examples 5 and 6).
These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes. Beverages to which ammonium iron citrate and collagen peptide were not added (Comparative Examples 5-1 and 6-1) were used as controls.
The beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
Figure JPOXMLDOC01-appb-T000006
Figure JPOXMLDOC01-appb-T000006
　表６に示したように、動物プラセンタである鮭由来プラセンタエキス、馬由来プラセンタエキスを配合すると沈殿が生じた（比較例５－１、６－１）。鮭由来プラセンタエキス、馬由来プラセンタエキスの沈殿生成はクエン酸鉄アンモニウムの配合だけでは抑制できなかったが（比較例５－２、６－２）、比較例５－１と実施例５、比較例６－１と実施例６を比較して明白なように、鉄化合物にさらにコラーゲンを配合することで沈殿生成が抑制された。 As shown in Table 6, precipitation occurred when salmon-derived placenta extract and horse-derived placenta extract, which are animal placenta, were blended (Comparative Examples 5-1 and 6-1). Precipitation formation of salmon-derived placenta extract and horse-derived placenta extract could not be suppressed only by the addition of ammonium ferric citrate (Comparative Examples 5-2 and 6-2), but Comparative Example 5-1 and Example 5 and Comparative Example. As is clear from the comparison between 6-1 and Example 6, precipitation formation was suppressed by further adding collagen to the iron compound.
　表６の通り、豚由来動物プラセンタエキスに代えて、メロン胎座由来植物プラセンタエキスを配合し表１又は表３の調製と同様の方法にて飲料を得た（比較例７－１～８－２）。
　これらの飲料をスクリュー管Ｎｏ．７（（株）マルエム製）に５０ｍｌ充填し、８０℃２５分の殺菌を行った。上記の通り調製した飲料を６５℃で７日間保存し、沈殿を目視により観察した。表２の基準で沈殿生成度合いを評価した。
　クエン酸鉄アンモニウム及びコラーゲンペプチドを添加しない飲料（比較例７－１、８－１）を対照とした。
Figure JPOXMLDOC01-appb-T000007
 As shown in Table 6, instead of the pig-derived animal placenta extract, the melon placenta-derived plant placenta extract was blended to obtain a beverage by the same method as the preparation in Table 1 or Table 3 (Comparative Examples 7-1 to 8-). 2).
These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes. The beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
Beverages to which ammonium iron citrate and collagen peptide were not added (Comparative Examples 7-1 and 8-1) were used as controls.
Figure JPOXMLDOC01-appb-T000007
　表７に示した通り、植物プラセンタエキスの配合により沈殿が生じたが（比較例７-１、８－１）、鉄化合物およびコラーゲンペプチドを配合した場合でも沈殿生成抑制効果は得られなかった（比較例７－２～７－４、８－２）。 As shown in Table 7, precipitation was caused by the addition of the plant placenta extract (Comparative Examples 7-1 and 8-1), but the effect of suppressing the precipitation was not obtained even when the iron compound and the collagen peptide were added (Comparative Examples 7-1 and 8-1). Comparative Examples 7-2 to 7-4, 8-2).
　本発明により、飲料中における動物プラセンタエキス由来の沈殿を抑制することが可能となったので、医薬品、医薬部外品及び食品の分野において、商品性の高い動物プラセンタエキス含有飲料を提供することが期待される。 INDUSTRIAL APPLICABILITY Since the present invention has made it possible to suppress precipitation derived from animal placenta extract in beverages, it is possible to provide beverages containing animal placenta extract with high commercial value in the fields of pharmaceuticals, quasi-drugs and foods. Be expected.

Claims (10)

  1. 動物プラセンタエキス、及び鉄化合物を含有し、炭水化物含有量が４０ｗ／ｖ％以下である飲料。 A beverage containing animal placenta extract and an iron compound and having a carbohydrate content of 40 w / v% or less.
  2. さらにコラーゲンペプチドを含有する請求項１に記載の飲料。 The beverage according to claim 1, further containing a collagen peptide.
  3. 鉄化合物の含有量が、鉄換算で０．０００２～０．２ｗ／ｖ％である請求項１または２に記載の飲料。 The beverage according to claim 1 or 2, wherein the content of the iron compound is 0.0002 to 0.2 w / v% in terms of iron.
  4. 鉄化合物が、フマル酸第一鉄、塩化第二鉄、クエン酸鉄、クエン酸鉄アンモニウム、クエン酸第一鉄ナトリウム、グルコン酸第一鉄、乳酸鉄、ピロリン酸第一鉄、ピロリン酸第二鉄、硫酸第一鉄およびヘム鉄からなる群から選ばれる少なくとも１種である請求項１～３のいずれかの項に記載の経口液体組成物。 The iron compounds are ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, sodium ferrous citrate, ferrous gluconate, iron lactate, ferrous pyrophosphate, and ferric pyrophosphate. The oral liquid composition according to any one of claims 1 to 3, which is at least one selected from the group consisting of iron, ferrous sulfate and hem iron.
  5. 動物プラセンタエキスの含有量が、０．００１～４ｗ／ｖ％である請求項１～４のいずれかの項に記載の飲料。 The beverage according to any one of claims 1 to 4, wherein the content of the animal placenta extract is 0.001 to 4 w / v%.
  6. 動物プラセンタエキスの含有量が、胎盤換算で０．０２５～１００ｗ／ｖ％である請求項１～５のいずれかの項に記載の飲料。 The beverage according to any one of claims 1 to 5, wherein the content of the animal placenta extract is 0.025 to 100 w / v% in terms of placenta.
  7. コラーゲンペプチドの含有量が、０．０２～２０ｗ／ｖ％である請求項２～６のいずれかに記載の飲料。 The beverage according to any one of claims 2 to 6, wherein the content of collagen peptide is 0.02 to 20 w / v%.
  8. ｐＨが２．５～４．５である請求項１～７のいずれかの項に記載の飲料。 The beverage according to any one of claims 1 to 7, wherein the pH is 2.5 to 4.5.
  9. 動物プラセンタエキスを含有する飲料において、鉄化合物を添加することを特徴とする沈殿生成抑制方法。 A method for suppressing precipitation formation, which comprises adding an iron compound to a beverage containing an animal placenta extract.
  10. 動物プラセンタエキスを含有する飲料において、鉄化合物及びコラーゲンペプチドを添加することを特徴とする沈殿生成抑制方法。 A method for suppressing precipitation formation, which comprises adding an iron compound and a collagen peptide to a beverage containing an animal placenta extract.
PCT/JP2021/041452 2020-11-19 2021-11-11 Beverage containing placenta and iron WO2022107673A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021576325A JP7112040B1 (en) 2020-11-19 2021-11-11 Beverages containing placenta and iron
JP2022008167A JP2022081472A (en) 2020-11-19 2022-01-21 Beverage including placenta and iron

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-192121 2020-11-19
JP2020192121 2020-11-19

Publications (1)

Publication Number Publication Date
WO2022107673A1 true WO2022107673A1 (en) 2022-05-27

Family

ID=81708827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/041452 WO2022107673A1 (en) 2020-11-19 2021-11-11 Beverage containing placenta and iron

Country Status (2)

Country Link
JP (2) JP7112040B1 (en)
WO (1) WO2022107673A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11221047A (en) * 1997-10-29 1999-08-17 Masakazu Matsushima Placenta extract-containing liquid agent
WO2005107734A1 (en) * 2004-05-06 2005-11-17 Taiyokagaku Co., Ltd. Alcohol metabolism accelerating composition, and food or drink containing the composition
JP4715078B2 (en) * 2003-04-16 2011-07-06 大正製薬株式会社 Liquid composition for internal use containing iron compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11221047A (en) * 1997-10-29 1999-08-17 Masakazu Matsushima Placenta extract-containing liquid agent
JP4715078B2 (en) * 2003-04-16 2011-07-06 大正製薬株式会社 Liquid composition for internal use containing iron compounds
WO2005107734A1 (en) * 2004-05-06 2005-11-17 Taiyokagaku Co., Ltd. Alcohol metabolism accelerating composition, and food or drink containing the composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Frozen Smoothie. Record number (ID#) 2983877. Mintel GNPD. 2015, [online], [retrieved on 21 December 2021], Retrieved from the Internet: <URL: https://www.gnpd.com/sinatra/recordpage/2983877/> in particular, Product name, raw material name and nutritional facts label in the product photo *

Also Published As

Publication number Publication date
JP2022081472A (en) 2022-05-31
JPWO2022107673A1 (en) 2022-05-27
JP7112040B1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
TW201204268A (en) Substantially clear nutritional liquids comprising calcium HMB and soluble protein
JPWO2005084461A1 (en) Mineral-containing acidic protein food and drink
WO1994009650A1 (en) Bifidobacterium growth promoter
JP5465834B2 (en) Liver function protectant
CN103976023A (en) Okra yogurt beverage and preparation method thereof
JP2006180812A (en) Jelly beverage
CN104768384B (en) Concentrate the milkiness acidic beverages and its manufacture method of type
JP7082237B1 (en) Beverages containing collagen and iron
JPH07222571A (en) Food/beverage for athlete
JP7112040B1 (en) Beverages containing placenta and iron
JP2007215498A (en) Drink for pregnant woman
JP6841371B1 (en) Iron compound and collagen-containing composition
CN107495050A (en) A kind of mulse
JP6025538B2 (en) Branched-chain amino acid degradation odor inhibitor and degradation odor control method
JP2021090412A (en) Unpleasant taste masking agent, acidic protein beverage, unpleasant taste masking method, and method for producing acidic protein beverage
JP6498830B1 (en) Beverages containing processed cocoa beans
JP2022081425A (en) Iron compound-containing composition
JP2022151696A (en) Beverage containing iron compound and collagen
JP2022151697A (en) Beverages containing iron compounds and ceramides
US20120178673A1 (en) Fat accumulation suppressor
JPH11243914A (en) Food or beverage promoting calcium absorption
JPH05207865A (en) Nutrition-supplying food containing natural vitamin c in high unit
KR102237526B1 (en) Garlic fermentation composition using lactobacillus brevis wikim47 with superior ornithine productivity
JP2016039803A (en) Zinc and copper fortifying composition, hydrating supplement, and process for preparing the same
JP2022151695A (en) Beverages containing iron compounds and ceramides

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2021576325

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21894547

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21894547

Country of ref document: EP

Kind code of ref document: A1